

October 2023



burjeel
holdings

Earnings Presentation



Q3 & 9M 2023

Leading Super-Specialty Healthcare
Provider in the MENA

Disclaimer

This presentation has been prepared by Burjeel Holdings PLC based on publicly available information and non-public information to assist you in making a preliminary analysis of the content referenced herein solely for informational purposes. It should not be construed as an offer to sell or a solicitation of an indication of interest to purchase any equities, security, option, commodity, future, loan or currency including a private sale of shares in the Company (the “**Financing Instruments**”).

It is not targeted to the specific investment objectives, financial situation or particular needs of any recipient. It is not intended to provide the basis for any third-party evaluation of any Financing Instrument or any offering of them and should not be considered as a recommendation that any recipients should subscribe for or purchase any Financing Instruments. The recipient agrees to keep confidential any information contained herein and any other written or oral information otherwise made available in connection with any potential transaction related to this presentation and shall not reproduce, publish, distribute or otherwise divulge such information to any other person(s) other than in accordance with any applicable non-disclosure agreements executed by the recipient with the Company.

None of the Company or its subsidiaries or any of their affiliates or advisors make any representation or warranty as to the fairness, accuracy, adequacy or completeness of the information, the assumptions on which it is based, the reasonableness of any projections or forecasts contained herein or any further information supplied or the suitability of any investment for your purpose. None of the Company or any of its affiliates or advisors, or their respective directors, officers or employees, share any responsibility for any loss, damage or other result arising from your reliance on this information. Each of the Company, its subsidiaries, their affiliates and advisors therefore disclaim any and all liability relating to this presentation including without limitation any express or implied representations or warranties for statements contained in, and omissions from, the information herein. No recipient of this presentation should rely upon any information contained in this presentation, including but not limited to any historical financial data, forward looking statements, forecasts, projections or predictions. The Company, its subsidiaries, their affiliates and advisors are acting solely in the capacity of an arm’s length counterparty and not in the capacity of your financial advisor or fiduciary. Nothing in this presentation should be construed as legal, tax, regulatory, accounting or investment advice. The recipients should seek and rely upon the advice of its own professionals and other advisors for such matters.

Contents


01
Financial
Highlights

02
Strategy
Execution

03
Performance
Review

04
Guidance

05
Q&A
Appendix





burjeel
holdings

01




Financial Highlights


Leading Super-Specialty Healthcare Provider in the MENA

Leading Integrated Healthcare Network in the MENA

Significant scale and market presence



Diversified portfolio of brands



Strong financial performance, 9M 2023



>30%
Revenue from complex specialty care⁵

Notes: (1) As at 30 October 2023. (2) Inpatient share of private market in the UAE based on data shared by Burjeel's management and JLL Healthcare research and analysis. (3) As at 30 September 2023. (4) Based on 9M 2023 (5) Oncology, Orthopaedics and Spine, Women's Care, Paediatrics, NeuroSurgery & Neurology, Cardiac Sciences. Based on FY 2022.

Q3 & 9M 2023

Financial & Operational Highlights

Financial Highlights



Revenue

Q3'23

AED **1,155m**

↗ **23.8%** YoY



EBITDA

Q3'23

AED **260m**

↗ **34.1%** YoY



Net Profit

Q3'23

AED **137m**

↗ **162.6%** YoY



Group FCF

9M'23

AED **331m**

↗ **55.8%** YoY

Operational Highlights



Expanding Patient Footfall

In-patient and out-patient footfall grew by 19.7% and 10.4% YoY in 9M'23, respectively



Leejam Partnership

First four premier PhysioTherabia centers opened in Riyadh, KSA



State-of-the-Art Technology Investment

BMC introduced cutting-edge da Vinci Xi robotics, ensuring precise, efficient minimally invasive procedures



Oracle Health

Awarded Oracle Health an AED 125 million contract for a cutting-edge Medical Record System



burjeel
holdings

02



Strategy Execution

Leading Super-Specialty Healthcare Provider in the MENA

PhysioTherabia – Entering High Potential KSA Market

Highly attractive entry proposition



60+ Physical therapy, rehabilitation and wellness **centers in 12 KSA cities** in a joint venture (50:50) with Leejam Company

PhysioTherabia centers unlock significant value creation

Leejam’s extensive network of fitness centers across KSA, enables an **Asset-light low-CAPEX model**, with high EBITDA margins and ROI

Unlocks **access to Leejam’s well-established 300k+ member base**, with complementary service offerings

Provides **strong foundation for further KSA expansion opportunities**, through a limited risk proposition



Targets in KSA	Number of centers (2023-2025)	Annual revenue per center	CAPEX per center
Physio & infusion centers	50	SAR 8-10 m	~ SAR 1.2–1.8 m
Flagship centers	10	SAR 10-12 m	~ SAR 2.5–3.5 m
Center profile	80% +utilization ramp-up after 24 months. EBITDA breakeven after 12 months.		

Launched first premier physiotherapy centers



4 centers launched in Riyadh¹

Centers to be launched



2023: 6 Centers + 2024-2025: 54 Centers = Mid-term target (2026-2027)²: SAR 600m Revenue annually, 30% EBITDA margin

Note: (1) Centers launched are Riyadh’s Olaya View Fitness Time, Al Munsiyah Men’s Gym, Al Munsiyah Ladies Gym & Al Taawon Men’s Gym. (2) Burjeel Holdings has a consolidation right for PhysioTherabia financials. The CAPEX and net profit will be shared with Leejam Company (50:50).

Expanding Our UAE Healthcare Infrastructure

Launch of 5 new medical centers in FY2023-Q1 2024



The planned launch of five new medical centers will allow the group to tap into new markets and attract more patients, resulting in increased revenue streams and improved profitability. Burjeel will also benefit from economies of scale and greater operational efficiencies, as we can leverage our existing infrastructure and resources across multiple locations.

Center Name	Launch Period	No. of revenue generating doctors
Al Dhafra Day Surgery Center	Q1 2024	16 doctors
Medical Center Gayathi	Q1 2024	22 doctors
Burjeel Aesthetic & Smart Clinic ¹	Expected launch: Q3 2023	1 doctor
Dubai Satellite Clinic (Al Quoz)	Q3 2023	8 doctors
Dubai Satellite Clinic (DIP-2 Mango)	Q4 2023	7 doctors

In FY2023 - H1 2024, we will also be adding ~80 specialized in demand beds across our network of matured facilities:
48 beds opened in Q3'23

+13 Launched
Burjeel Hospital, Abu Dhabi

+12 Launched
Burjeel Medical Center, Deerfield's

+16
Burjeel Day Surgery Center, Al Reem

+8
LLH Hospital, Abu Dhabi

+7 Launched
LLH Salalah

+16 Launched
Burjeel Royal Hospital, Al Ain

+12
Al Dhafra Day Surgery Center




Note: In the UAE, three new medical centers opened since the beginning of 2023: Lifecare Medical center Tasneem, LLH Medical Center Gayathi and Dubai Satellite Clinic (Al Quoz).
(1) Clinic under ADNOC, managed by Burjeel.


Leveraging Digital Transformation to Enhance Patient Experience and Maximise Operational Efficiency

Strategic digital initiatives

- Mid-term key investment areas in Digital Health
- Oracle Health information system to be fully implemented across the Group over next 3 years with total capex of AED 125m



Key digital achievements



Patient digital channel

Mobile application



Note: (1) Includes Medeor Dubai, Burjeel Dubai and Burjeel Sharjah.



burjeel
holdings

03





Performance Review


Leading Super-Specialty Healthcare Provider in the MENA

Accelerated Top-line Growth & Enhanced EBITDA Margin

Group revenue growth, AED m



Group EBITDA growth, AED m



Breakdown in change, AED m:



Hospitals



Medical centers




Pharmacies & other

Increasing Patient Footfall & Ramping Up Bed Occupancy

Group outpatient footfall, k

% OP utilisation

72% 69% 74% 71%




- Hospitals and medical centers contributed to an 10.4% increase in group 9M '23 outpatient footfall, with **cross-group referral** a key pillar of our operating strategy.
- There was a slight drop in outpatient capacity utilization despite an increase in footfall, due to the hiring of new physicians in operating units.



Group inpatients footfall, k

% bed occupancy

62% 63% 54% 60%




- The 19.7% increase in inpatient footfall in 9M '23 drove increased inpatient utilization to 60%. This was largely driven by BMC.
- 3,560 key complex surgeries completed in 9M '23, comprising seven core categories of surgery, an increase of 2% YoY.
- Growth in inpatient footfall was further driven by Burjeel Hospital Abu Dhabi, LLH Hospital Abu Dhabi and Burjeel Royal Hospital Al Ain, as a result of the **continued ramp up and introduction of new services**.




Burjeel Medical City Performance


Total patients, k



Revenue, AED m¹




EBITDA, AED m¹



Burjeel Medical City (BMC) is a key driver of Burjeel's wider ambition and our ability to deliver increasingly complex care and high-value, high-yield services. **BMC contributed 24%** to total hospital segment revenue in 9M '23. The **continued ramp up of BMC** in the current period **drove a sharp increase in IP and OP footfalls**, as a result of the introduction and rapid ramp-up of new services.


Well-Invested Manpower Driving Margin Expansion

Group OPEX breakdown¹, as % of revenue



- Revenue growth substantially outpacing OPEX (+23.8% vs +20.9% in Q3 '23) thanks to optimization of other expenses and controlling recruitment costs.
- Employee expenses were flat as a proportion of revenue despite **66 total doctors being added** between July and September 2023 to **build capability in high-value areas** and add to its super specialty service mix.

EBITDA growth , AED m




- 19.5% growth in 9M '23 EBITDA enabled by **strong Q3 revenue growth** and the delivery of increasingly high value care.
- Q3 '23 EBITDA margin has shown significant improvement due to growing patient footfall and strong topline growth. The business continues to **enable top line growth through investment in highly-skilled talent** recruitment and training.

Strong Cash Flow Conversion


Free cash flow¹, AED m

% FCF conversion²



AED m	2019	2020	2021	2022	9M '22	9M '23
EBITDA	418	470	779	878	608	727
Change in NWC	157	(5)	(196)	(429)	(346)	(303)
Maintenance CAPEX	(35)	(18)	(86)	(83)	(50)	(93)

Cash flow from operating activities, AED m




Commentary

- **Improvement in operating cash flow (+64.0%)** driven by high EBITDA growth and optimised NWC investments in 9M '23.
- **In 9M '23, maintenance CAPEX increased** due to the purchase of medical equipment and leasehold improvements.
- **FCF cash conversion improved by 106bps** with high level of ROCE (19%) in 9M '23.

Maintaining a Robust Balance Sheet

AED m	FY2021	FY2022	9M '23
Bank balances and cash	134	150	94
Interest bearing loans and borrowings	3,208	1,261	1,186
Bank overdraft	91	-	-
Bank debt¹	3,299	1,261	1,186
Net debt	3,165	1,111	1,092
Lease liabilities ²	1,281	1,176	1,177
Net debt including lease liabilities³	4,447	2,286	2,269
Amounts due from / (to) related parties	1,542	(12)	(8)
KPIs:			
Net debt including lease liabilities ³ / EBITDA	5.7x	2.6x	2.3x
Net debt / pre-IFRS 16 EBITDA⁴	4.9x	1.5x	1.3x
Total group equity	381	1,118	1,378
Divided mainly into:			
Share capital	0.7	521	521
Shareholders' account	533	-	-
Share premium	-	367	367
Retained earnings (incl NCI)	(175)	224	484

Debt maturity as of 30 September 2023




Commitment to a conservative financial policy

- **Net debt / pre-IFRS 16 EBITDA LTM ratio as of 30 September 2023 is 1.3 vs. 1.5x** as of 31 December 2022. Decreased due to IPO proceeds and NWC optimization. No contingent off-balance sheet liabilities.
- **Average finance cost rate of 7.1%** (as of 9M '23), which the majority effectively hedged till 2030.
- **Amounts due from and to related parties** remains low, reflecting Burjeel's strong governance and operational independence.
- **The Company's share capital is AED 521 million** as of 9M '23.

Robust Net Profit Margin to Deliver Healthy Return to Shareholders

Net profit evolution, AED m



Commentary

- **Asset-light cash generative model**
underpins significant dividend paying capacity
- **Dividend policy:**
pay cash dividends from 2023 onwards, on the expected basis of a pay-out ratio of 40% to 70% of net profit, dependent on the required investment for additional growth plans
- **The Group paid out AED 95 million**
as the debut interim dividend for H1'23
- **Record date:**
August 14, 2023
- **Payable date:**
August 31, 2023



AED 225m

H1'23 Net profit

42%

Dividend pay-out ratio

AED 95m

Interim dividends
for H1'23

AED 0.02

Interim dividends
per share for H1'23



burjeel
holdings

04



Guidance

Leading Super-Specialty Healthcare Provider in the MENA

Guidance

FY2023

Mid-term (2024-2027)



Expansion

- UAE Medical centers¹: **5**
- UAE Additional beds: **80**
- KSA PhysioTherabia centers: **up to 6**

- KSA PhysioTherabia centers: **54**



Revenue growth

- **High-teens Group** revenue growth
- **+50% BMC** revenue growth

- **Group** revenue growth to **gradually normalize from mid-teens to high-single-digit** over time as key assets mature, including:
 - **BMC** to continue to ramp up to **reach AED ~2bn** revenue p.a.
 - **KSA expansion** project to **reach AED ~600m** revenue p.a.



EBITDA margin

- **Group** EBITDA margin to **improve to at least 2021 levels (~23%)**
- **BMC** EBITDA margin expected to **improve to mid-high teens**

- **Group** EBITDA margin to **gradually expand to high-20s**
- **Driven by** ramp-up of growth assets, asset-light international expansion, as well as focus on increasing patent yield and operational excellence



CAPEX

- **Maintenance CAPEX** expected to be **<2.5%** of revenue²
- **Additional cumulative investment of ~AED 85m** for digital transformation and UAE & KSA expansion³

- **Maintenance CAPEX** expected to be **<2.5%** of revenue²
- **Additional cumulative investment of ~AED 215m** expected **until 2027** to support digital transformation and KSA expansion³



Leverage

- Net leverage⁴ of **<2.5x** to be maintained
- Net leverage⁴ of **1.3x** as of September 2023

- Net leverage⁴ of **<2.5x** to be maintained



Dividends

- **Payout ratio of 40-70%** of net income, dependent on required investment for potential additional growth
- **First interim dividend paid** in August 2023 on the basis of H1 2023 net income

- **Payout ratio of 40-70%** of net income, dependent on required investment for potential additional growth



burjeel
holdings

05




Q&A

Appendix


Leading Super-Specialty Healthcare Provider in the MENA

Large, Growing and Resilient Addressable Market



UAE & Oman & KSA market size¹

Total healthcare expenditure (USD bn)



UAE Market Leader with a Prominent Position Across Segments

#1 inpatient platform in the UAE
by private market volumes

Focus on specialised and complex
care resulting in growing market share

Excellent reputation and capabilities resulting in strong
positioning to **benefit from increasing medical tourism**

Private sector operator holding **4 hospitals with**
license for **Emergency and Trauma**

Unique positioning and offering of **BMC as the largest**
hospital in the UAE with specialised oncology offering

Leading cancer research center
in the UAE

Number of beds by key players¹, as of December 2022



Estimated private market share (UAE)⁴



Notes: (1) Based on Company data, public sources and JLL research and analysis. Does not include the recently formed ADQ backed Pure Health healthcare platform. (2) LTC – Long term care. (3) Excluding O&M beds of Sheikh Khalifa hospital. (4) Based on Company data, Industry report from IPO Prospectus and JLL Healthcare research and analysis.

Creating Differentiating Healthcare System



Burjeel Medical City – the UAE Leader in Complex Care

Overview and complex care specialties

~24%
Revenue contribution



60+
Specialties

400
Beds

258
Doctors

**KYPROS
NICOLAIDES**
Fetal Medicine & Therapy Center
a burjeel holdings company

عيادة بالي الشرق الأوسط
MIDDLE EAST CLINIC
Abu Dhabi, UAE
a burjeel holdings company

ifem MIDDLE EAST CLINIC
ENDO
a burjeel holdings company

Advanced Gynecology Institute

ESMO Novalis Certified

Burjeel Medical City is the only ESMO in the UAE and Novalis Certified accredited center in the GCC

Note: Revenue contribution as a percentage of total hospital segment revenue for 9M '23 (pre-intersegment eliminations).

- 1 **Oncology**
Only advanced cancer center in Abu Dhabi to be accredited by the European Society for Medical Oncology
- 2 **Trauma**
Level 1 Trauma Center; First private hospital in UAE to be equipped with helipad for emergency transfers
- 3 **Fetal**
First comprehensive center for Fetal Medicine and Therapy in the UAE, set up in collaboration with Kypros Nicolaides
- 4 **Cross Specialty Innovation**
Stem Cell Cryopreservation, Integrated Center for Research for Rare Diseases, MRI for Neuro-Oncology Surgeries, State of the art centralized laboratories, radiotherapy and diagnostics services
- 5 **Pediatrics**
Level III Tertiary NICU and Level IV PICU including ECMO; Offers a comprehensive paediatrics program
- 6 **Long-term Acute Care/Dedicated Rehab**
UAE's largest long term acute care and rehab center; Hosts Burjeel Darak, an integrated center for long term care and rehabilitation
- 7 **Transplant**
UAE's leading multi-organ transplant center; First private hospital in the UAE to receive a license to provide organ transplants services

Complex medical care

Expansion through Asset-Light O&M Contracts

O&M opportunities in the UAE and MENA

Approach

- Partner with the **Ministry of Health, Department of Health and large public hospitals** to collaborate on O&M / department specific opportunities in the UAE and Africa including:
 - Construction:** procurement, installation of equipment and post construction handover
 - Operation and management:** day to day management of asset or department including systems implementation, staffing and training

Economics

- Zero Opex & CAPEX investments** generating high ROI
- Benefits from %-based O&M payments**, with strong upside as population and economic activity grows

Outlook


- Solid mid-term contract pipeline** (up to 10 hospitals and medical centers)
- O&M segment is expected to **contribute up to 5% of the Group net profit** in the mid-term

Track record of successful O&M projects

<p>Al Dhannah Hospital, Al Dhafra (ADNOC)</p> <ul style="list-style-type: none"> Located in the fast-growing industrial hub of Al Ruwais within the Western region of the UAE Unlocks access to underserved western region Al Dhannah Hospital will be a major referral source for BMC Significant high-value Thiqa patient population 	<p>200k+ Al Dhafra Region Population</p> <p>122 bed Multi-Specialty Hospital</p>
<p>Mafraq Hospital, Abu Dhabi</p> <ul style="list-style-type: none"> Provided doctors, nurses and paramedics, centralised support functions Deployed biomedical & IT infrastructure and utilised paperless documentation 	<p>1,850+ Patients</p> <p>270 Acute beds</p> <p>80 ICU beds</p> <p>16 PICU beds</p>
<p>Prosthetics & Orthotics Project, Ethiopia</p> <ul style="list-style-type: none"> Includes development of training center for Prosthetic & Orthotic practitioners Long-term vision to convert facility into a rehab hub in Ethiopia 	<p>6,000+ Patients</p> <p>2,000 Prosthetic</p> <p>~400 Assistive devices</p>
<p>Shabwa & Mocha, Yemen</p> <ul style="list-style-type: none"> Deployed highly skilled clinical / admin team, delivered training / education to local staff Focused on high complexity surgery / emergency management 	<p>12,300 Monthly patient footfall</p> <p>300 Total beds</p> <p>2 Facilities</p>
<p>Liberia Hospital</p> <ul style="list-style-type: none"> Acting as nodal agent on behalf of Government of UAE Provided experienced team of designers / engineers / technicians 	<p>1/3 OR/OT rooms</p> <p>88 Beds</p> <p>13 Urgent care rooms</p>

Financial Performance: Hospitals Segment

Revenue, AEDm¹



- Hospitals segment contributed 89% to Group revenue in 9M '23 comparable to the same period last year.
- Revenue growth of 16.9% was largely driven by Burjeel Medical City, Burjeel Day Surgery center, Burjeel Royal Hospital Al Ain, Burjeel Speciality Hospital Sharjah and Medeor Hospital Abu Dhabi.
- Revenue growth was also supported by the Group's focus on super specialty treatment and complex cases.


EBITDA, AEDm

Hospitals segment	9M '22	9M '23	Change
Inventories consumed	719	835	16.1%
% of revenue	27.4%	27.2%	
Doctors' and other employees¹	1,068	1,236	15.7%
% of revenue	40.7%	40.3%	
Provision for ECL	41	53	31.5%
% of revenue	1.5%	1.7%	
Other expenses²	289	279	(3.4%)
% of revenue	11.0%	9.1%	
Total OPEX ex.D&A³	2,117	2,404	13.5%
% of revenue	80.6%	78.3%	
EBITDA	508	666	31.1%
% EBITDA margin	19.4%	21.7%	

- Other expenses as a % of revenue declined substantially to 9.1% from 11.0% driven by ramp up of growth assets, as well as focus on increasing patent yield and operational excellence.
- Staff costs declined as a % of revenue mainly due to the ramp up of the Group's growth assets and higher utilization.

Financial Performance: Medical Centers Segment

Revenue, AEDm¹



- Burjeel-branded medical centers continued their robust performance, driving 15.0% revenue growth of this segment.
- In this segment, revenue growth is mainly driven by Burjeel Medical Center, Al Shamkha, Burjeel Medical Centre Deerfields, and Burjeel Medical Centre Zeina.
- Also saw a ramp-up in specialties like OBGYN, paediatric, orthopedics, physiotherapy, and internal medicine.

EBITDA, AEDm

Medical centers segment	9M '22	9M '23	Change
Inventories consumed	58	70	20.2%
% of revenue	20.8%	21.8%	
Doctors' and other employees¹	111	126	13.7%
% of revenue	39.5%	39.0%	
Provision for ECL	5	4	(27.1%)
% of revenue	1.9%	1.2%	
Other expenses²	29	30	2.9%
% of revenue	10.5%	9.4%	
Total OPEX ex.D&A³	203	230	12.9%
% of revenue	72.7%	71.4%	
EBITDA	76	92	20.6%
% EBITDA margin	27.3%	28.6%	

- EBITDA margin increased on the back of a decline in doctors' and other employees costs, provision for ECL and other expenses as a percentage of revenue.
- Direct cost as a percentage of revenue increased due to a change in revenue mix.

Group & Segment Summary

Q3 & 9M 2023

Group financial summary

AED millions	Q3 '23	Q3 '22	9M '23	9M '22
Revenue	1,155	933	3,317	2,832
OPEX ³	(899)	(743)	(2,607)	(2,238)
EBITDA⁴	260	194	727	608
Net profit	137	52	362	205
EBITDA margin	23%	21%	22%	21%
Net profit margin	12%	6%	11%	7%
Total equity	1,378	581	1,378	581
Net debt ⁵	1,092	1,821	1,092	1,821
Earnings per share (AED)	0.02	0.01	0.07	0.04
Capital employed	3,417	3,422	3,417	3,422
ROCE (LTM)	19%	16%	19%	16%
Net debt / EBITDA ⁶	2.3	3.6	2.3	3.6
Net debt excl. Lease Liabilities/ Pre-IFRS 16 EBITDA	1.3	2.5	1.3	2.5
Return on equity	37%	54%	37%	54%

Segmental financial summary

AED millions	Q3 '23	Q3 '22	9M '23	9M '22
Revenue	1,155	933	3,317	2,832
Hospitals ¹	1,028	820	2,945	2,499
Medical centers ¹	111	94	318	276
Pharmacies ¹	13	15	47	49
Others ²	3	4	7	8
EBITDA	260	194	727	608
Hospitals	238	162	666	508
Medical centers	34	30	92	76
Pharmacies	(0.1)	1	4	4
Others	(12)	1	(35)	20
Net profit	137	52	362	205
Hospitals	125	31	329	138
Medical centers	25	20	66	46
Pharmacies	(0.3)	0.5	4	3
Others	(13)	1	(37)	19

Notes: (1) Includes other operating income and other revenue represent the Non-Clinical revenue in Hospitals, Medical Center, Pharmacies segments which majorly include the O&M fee, fee for manpower supply contracts, and few other items. (2) Others contains revenue from entities who majorly provide the services to Hospitals, Medical Center, Pharmacies of the group and contain Central Purchase, Claim Care, Valet Parking etc. (3) OPEX includes G&A expenses and ECL. (4) EBITDA represents Earnings Before Interest, Tax, Depreciation and Amortization. (5) Bank debt incl. Bank overdraft less Cash and cash equivalents. (6) Bank debt and Lease liabilities less Cash and bank balance divided by overall EBITDA.

Strong Leadership with Well-Established Public Market-Oriented Corporate Governance

Highly experienced leadership with focus on growing shareholder value

Board of Directors

 Dr. Shamsheer Vayalil Founder and Non-Exec Chairman	 A H.E. Ahmed Jasim Yousif Naser Alzaabi Vice Chairman, Non-Exec Director	 B N H.E. Dr Thani bin Ahmed Al Zeyoudi Non-Exec Director	 A N Mr. Omran AlKhoori Executive Director	 B A N Dr. Ghuwaya Mohammed Khuwaidem Abdulla AlNeyadi Non-Exec Director
 N Dr. Mohan Chellappa Non-Exec Director	 A N Mr. Mohd Loay T. A Abdelfattah Non-Exec Director	XX – years at Burjeel XX – sector experience, years		

Strong governance framework

- ✓ BoD of 7 Members
- ✓ 70% Independent Directors
- ✓ 1 Female Board Director
- ✓ Aligned with SCA and ADX Regulations
- ✓ **Committees:**
 - B Business Development
 - A Audit
 - N Nomination and Remuneration

Management retention program

- ✓ **Annual compensation structure:**
 - 60% Financial KPIs – Net profit
 - 40% Functional KPIs – Individual for each role
- ✓ LTIP program to be adopted in Q1 2024

Management

 12 28 Mr. John Sunil Chief Executive Officer	 16 19 Mr. Muhammed Shihabuddin Chief Finance Officer	 17 17 Mr. Safer Ahamed Chief Operating Officer	 9 16 Mr. Omran AlKhoori President – Business Development	 3 18 Mr. Chetan Dev Sehgal Director – Strategy & Investments
 15 51 Dr. Nabil Mahmoud Mohammed Al Debouni Chief Medical Officer	 3 38 Mr. Pradeep Shivram Shilige Chief Technical Officer	 9 29 Dr. Mangalore Sanjai Kumar Group Head HR	 8 11 Mr. Mustasan Jaleel Basharat Mir General Counsel	

Prominent shareholder base

- | | |
|---|----------------------------------|
| 70.0%
VPS Healthcare Holdings | 5.0%
SYA Holdings |
| 14.4%
Quant Lase Lab (IHC) | 10.6%
Free float (ADX) |



burjeel
holdings

Investor Relations

October 2023



Sergei Levitskii

Head – Investor Relations

✉ sergei.levitskii@burjeelholdings.com

✉ ir@burjeelholdings.com

T: +971 2 3041 111

F: +971 2 2222 363

M: +971 503802383

PO Box: 7400, Abu Dhabi, UAE



[Investor Calendar](#)



[Company Website](#)